Resistant Hypertension

A polypill containing multiple blood pressure-lowering drugs may be an effective solution to addressing both uncontrolled hypertension and polypharmacy causing non-adherence to antihypertensive medications, speakers reported.

BOSTON —Small interfering RNA technology has the potential to become a novel treatment approach in cardiovascular medicine, according to Clyde W. Yancy, MD, MSc, MACP, MACC, FAHA, FHFSA.

BOSTON — A “laundry list of new trials” in cardiovascular medicine has led to “a decided portfolio of new ways of thinking, new interventions and a new potential to modify the natural history of CVD,” an expert said.

Idorsia announced that the FDA has approved aprocitentan, its antihypertensive drug, for treatment of hypertension in combination with other drugs in patients whose BP is not adequately controlled on other drugs.

Researchers reported that radiofrequency renal denervation is estimated to be cost-effective for uncontrolled hypertension despite multiple antihypertensive medications, at 13,482 British pounds per quality-adjusted life-years gained.

Promising new devices and emerging drug classes may improve BP control for some patients with difficult-to-treat hypertension, but clinicians must first address the structural inequities that impact access to care, according to a speaker.

A speaker reported that improved differentiation of resistant vs. refractory hypertension is essential in choosing optimal antihypertensive treatment, as the two represent different disease states of elevated blood pressure.

PHILADELPHIA — Obesity-associated dysregulated aldosterone is an endotype predictive of response to lorundrostat for patients with uncontrolled or treatment-resistant hypertension, according to data presented at ASN Kidney Week.

The patient is a 48-year-old man who presents to establish care with your practice. He has no specific symptoms to address. He recently moved to the area.